These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 12612979

  • 1. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
    Bianchi S, Bigazzi R, Caiazza A, Campese VM.
    Am J Kidney Dis; 2003 Mar; 41(3):565-70. PubMed ID: 12612979
    [Abstract] [Full Text] [Related]

  • 2. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
    [Abstract] [Full Text] [Related]

  • 3. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Abad S, Luño J.
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 7. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.
    Transplant Proc; 2005 Nov 10; 37(9):3808-12. PubMed ID: 16386546
    [Abstract] [Full Text] [Related]

  • 8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 10; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 9. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators.
    J Hypertens; 2009 May 10; 27(5):947-54. PubMed ID: 19318984
    [Abstract] [Full Text] [Related]

  • 10. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 10; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 11. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May 10; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 12. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group.
    Am J Cardiol; 2006 Sep 15; 98(6):768-73. PubMed ID: 16950182
    [Abstract] [Full Text] [Related]

  • 13. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 15; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov 15; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

  • 15. Effect of low doses of atorvastatin on the urinary peptide profile of kidney transplant patients.
    Pérez V, Navarro-Muñoz M, Bayés B, Lauzurica R, Pastor MC, Troya M, Bonet J, Ibernón M, Navarro M, Serra A, Núñez A, Romero R.
    Transplant Proc; 2009 Nov 15; 41(6):2111-4. PubMed ID: 19715847
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.
    Ozsoy RC, van der Steeg WA, Kastelein JJ, Arisz L, Koopman MG.
    Nephrol Dial Transplant; 2007 Jun 15; 22(6):1578-86. PubMed ID: 17347284
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
    Navarro-Muñoz M, Bonet J, Bayés B, Lauzurica R, Blanco S, Romero R.
    Transplant Proc; 2007 Sep 15; 39(7):2259-63. PubMed ID: 17889157
    [Abstract] [Full Text] [Related]

  • 19. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH, CARDS Investigators.
    Am J Kidney Dis; 2009 Nov 15; 54(5):810-9. PubMed ID: 19540640
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
    Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R.
    Aliment Pharmacol Ther; 2006 Jun 01; 23(11):1643-7. PubMed ID: 16696815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.